Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANF-RHO versus pegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in high-risk non-metastatic breast cancer
2016-001965-98Phase 2Terminated
- Sponsor
- Prolong Pharmaceuticals
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ANF-RHO and pegfilgrastim in chemotherapy-induced neutropenia (CIN) (3 arms), sponsored by Prolong Pharmaceuticals. Primary endpoint: Incidence of grade 3 or 4 neutropenia. Started Jan 2017; status: terminated.
02
Drugs
ANF-RHOpegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2016-001965-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001965-98.